What is the 13F Pro Quality Score for CHE?

13F Pro ranks CHEMED CORP (CHE) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View CHE's current score at https://13fpro.ai/company/CHE (free sign-up required for the full ranking).

Where does 13F Pro source CHE data?

All CHEMED CORP fundamentals and ownership data come directly from SEC EDGAR. CHEMED CORP files with the SEC under CIK 19584. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is CHE in?

CHEMED CORP (CHE) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

What drives CHE's revenue?

Per CHEMED CORP's latest 10-Q filed with the SEC on 2026-07-31, the biggest revenue drivers are: VITAS ($443.3M, +11.9% YoY); Roto-Rooter ($229.9M, +3.3% YoY); Routine home care ($391.3M, +9.3% YoY). Figures are extracted from the filing text and machine-verified against the document. Full breakdown at https://13fpro.ai/company/CHE.

How often is CHE research updated on 13F Pro?

CHE's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

CHEMED CORP(CHE)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →NYSEmid

Institutional-grade research for retail investors

SEC EDGAR: CIK 19584 CHE stock profile & AI dashboard →

13F Pro Quality Score

62.9/100

Rank #674 of 2,962 stocksTOP 25%

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.

Revenue Growth

47.3/100

Profitability

62.2/100

Balance Sheet

94.3/100

Earnings Quality

72.3/100

Free Cash Flow

60.6/100

Institutional Flow

76.3/100

Revenue Scale

67.2/100

Dilution Risk

45.9/100

Email me the moment this company reports earnings

AI Research Report

Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.

Upgrade to Pro

Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.

Why CHE Scores 63/100

exact factor attribution · 2026-09-11

CHE's composite is driven by capital efficiency and scale. Bars show each factor's exact push vs. a median company, using the same weights the ranking engine applies.

Capital efficiency

+4.4 pts

94th pct

Scale

+2.6 pts

67th pct

Earnings quality

+2.2 pts

72th pct

Profitability

+1.8 pts

62th pct

Free cash flow

+1.6 pts

61th pct

Institutional flow

+1.3 pts

76th pct

Shareholder dilution

-0.2 pts

46th pct

Earnings growth

-0.3 pts

44th pct

Revenue growth

-0.5 pts

47th pct

Latest change (2026-07-31): 67 → 67 · ↓ Revenue growth 90→78

Factor percentiles are cross-sectional ranks across the ~2,800-stock scored universe, computed from SEC EDGAR filings. Not investment advice.

CHE Stock Analysis & AI Quality Score

Data updated 2026-09-11

AI stock analysis and institutional research for CHEMED CORP (CHE), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores CHE at 62.9/100 on a 32-signal composite quality model, placing it at rank #674 of 2,962 stocks — the top 25% of the AI-ranked universe. CHE scores in the top quartile across balance sheet strength (94.3), institutional flow (76.3). Shareholder dilution risk is elevated at 45.9/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), CHEMED CORP reports quarterly revenue of $673.3M, net income of $67.7M, an operating margin of 13.3%. Top institutional holders of CHE by reported 13-F value include BlackRock, AQR CAPITAL MANAGEMENT, VANGUARD PORTFOLIO MANAGEMENT, based on the most recent SEC filings. CHE trades on the NYSE exchange and files with the SEC under CIK 19584. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate CHE daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for CHEMED CORP directly from SEC EDGAR. CHEMED CORP's 13F Pro composite quality score has ranged between 55 and 75 since 2021, currently 62.9 — a declining long-term trajectory across 68 quarterly and live scoring snapshots.

✦

Fun facts about CHEMED CORP

Quirks, history, and lore behind CHE — the kind of stuff that makes a stock memorable.

1
The Basics
A U.S. healthcare holding company · listed on the NYSE · headquartered in Cincinnati, Ohio · operates across two very different healthcare businesses.
2
The Numbers
Annual revenue in the low single-digit billions, with a market cap comfortably in the mid-cap range — not a giant, but not a nobody either.
3
The History
The company traces its roots back decades through a series of acquisitions and spin-offs, ultimately landing on a corporate structure that pairs plumbing and end-of-life care under one roof — yes, really.
4
The Secret
One of its two arms is a nationwide hospice and palliative care provider, making it one of the largest players in the business of helping patients spend their final days comfortably.
5
The Lore
The other arm is a plumbing and drain cleaning services giant — think clogged pipes — making this one of the most philosophically extreme conglomerates on any exchange.
6
The Giveaway
Parent company of VITAS Healthcare — one of America's largest hospice providers — and Roto-Rooter, the iconic drain-cleaning brand. From deathbeds to drainpipes, it does it all.

▶ Think you know your stocks? Play the Daily Ticker

What's Driving CHE's Business? Latest 10-Q Breakdown

✓ 27/27 datapoints verified

AI-extracted from CHEMED CORP's 10-Q filed 2026-07-31 — Q2 FY2026 (quarter ended June 30, 2026). Every figure is machine-verified against the filing text on SEC EDGAR.

Chemed's Q2 FY2026 revenue rose 8.8% to $673.3M, led by VITAS's 11.9% growth (6.1% more days-of-care, smaller Medicare Cap drag), while Roto-Rooter grew a slower 3.3% as water restoration fell 6.0%.

Biggest Revenue Drivers

VITAS$443.3M+11.9% YoY

6.1% increase in days-of-care, ~2.4% higher Medicare reimbursement rate, and a $15.9M smaller Medicare Cap billing limitation than the prior-year quarter

Roto-Rooter$229.9M+3.3% YoY

Increase in plumbing, drain cleaning and excavation offset by a decrease in water restoration

Biggest Revenue Drivers

Total revenue: $673.3M+8.8% YoY

VITAS$443.3M+11.9% YoY

6.1% increase in days-of-care, ~2.4% higher Medicare reimbursement rate, and a $15.9M smaller Medicare Cap billing limitation than the prior-year quarter

Within VITAS

Routine home care$391.3M+9.3% YoY

Continuous care$19.4M-18.0% YoY

Acuity mix shift negatively impacted revenue growth by 115 basis points in the quarter

Roto-Rooter$229.9M+3.3% YoY

Increase in plumbing, drain cleaning and excavation offset by a decrease in water restoration

Within Roto-Rooter

Water restoration$46.9M-6.0% YoY

Largest Expense Items

Cost of services provided and goods sold (excl. depreciation)$451.8M

SG&A before long-term incentive compensation and deferred comp market value adjustments$109.3M+10.9% YoY

$2.9M from increased Roto-Rooter advertising and $1.3M from increased legal expenses mainly at VITAS

Interest expense$1.8M

Increase related to higher long-term debt from stock repurchases and Roto-Rooter acquisitions

Margins: Consolidated gross margin rose to 32.9% in Q2 2026 from 29.8% in Q2 2025; VITAS margin improved to 23.8% from 19.1%, aided by a $15.9M smaller Medicare Cap billing limitation, while Roto-Rooter margin rose to 50.4% from 49.0%.

Watch Items from the Filing

Combined Medicare, Medicaid, and managed Medicaid receivables represent approximately 76% of consolidated net accounts receivable as of June 30, 2026.
Company added $140.0 million in long-term debt for the first time under a new credit facility, primarily funding $89.8 million of Q2 share repurchases and four Roto-Rooter franchise acquisitions.
VITAS continuous care revenue fell 18.0% YoY to $19.4 million amid a negative acuity mix shift.
Roto-Rooter water restoration revenue declined 6.0% YoY to $46.9 million.
VITAS reached a settlement, fully covered by cybersecurity insurance, for consolidated class actions from the October 24, 2025 data breach, for a non-material amount.

AI-extracted and verified against SEC EDGAR filing text. Not investment advice.

Read the full 10-Q on SEC EDGAR →Share on X

Revenue

Q2 2026

$673.3M

Net Income

Q2 2026

$67.7M

Free Cash Flow

Q2 2026

$69.3M

Operating Margin

Q2 2026

13.3%

ROIC

Q2 2026

36.8%

D/E Ratio

Q2 2026

0.17

Period

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro

Revenue

+4.1% YoY

$2.53BFY 2025

FY22 $2.13BFY23 $2.26BFY24 $2.43BFY25 $2.53B

Net Income

-12.2% YoY

$265.2MFY 2025

FY22 $249.6MFY23 $272.5MFY24 $302.0MFY25 $265.2M

Operating Income

-7.7% YoY

$338.2MFY 2025

FY22 $343.5MFY23 $340.6MFY24 $366.5MFY25 $338.2M

EPS (Diluted)

-7.8% YoY

$18.34FY 2025

FY22 $16.53FY23 $17.93FY24 $19.89FY25 $18.34

Total Assets

-7.8% YoY

$1.54BFY 2025

FY22 $1.44BFY23 $1.67BFY24 $1.67BFY25 $1.54B

Total Debt

—FY 2025

FY22 $102.5MFY23 —FY24 —FY25 —

Op. Cash Flow

-7.0% YoY

$388.3MFY 2025

FY22 $309.9MFY23 $330.3MFY24 $417.5MFY25 $388.3M

Free Cash Flow

+20.4% YoY

$325.5MFY 2025

FY22 $248.0MFY23 $273.4MFY24 $270.3MFY25 $325.5M

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Revenue	$2.53B +4.1%	$2.43B +7.4%	$2.26B +6.1%	$2.13B -0.2%	$2.14B +2.9%	$2.08B
Net Income	$265.2M -12.2%	$302.0M +10.8%	$272.5M +9.2%	$249.6M -7.0%	$268.6M -15.9%	$319.5M
Operating Income	$338.2M -7.7%	$366.5M +7.6%	$340.6M -0.9%	$343.5M +0.1%	$343.0M -12.0%	$389.7M
EPS (Diluted)	$18.34 -7.8%	$19.89 +10.9%	$17.93 +8.5%	$16.53 -1.9%	$16.85 -13.5%	$19.48
Total Assets	$1.54B -7.8%	$1.67B +0.0%	$1.67B +15.7%	$1.44B +7.4%	$1.34B -6.4%	$1.43B
Total Debt	—	—	—	$102.5M -44.6%	$185.0M	—
Operating Cash Flow	$388.3M -7.0%	$417.5M +26.4%	$330.3M +6.6%	$309.9M +0.4%	$308.6M -36.9%	$489.3M
Free Cash Flow	$325.5M +20.4%	$270.3M -1.1%	$273.4M +10.3%	$248.0M -0.8%	$249.9M -41.5%	$427.5M

Get alerted when CHE's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for CHEMED CORP including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of CHE

BlackRock, Inc.
$691.3M1,484,282 sh
AQR CAPITAL MANAGEMENT LLC
$446.2M972,474 sh
VANGUARD PORTFOLIO MANAGEMENT LLC
$366.6M787,068 sh
VANGUARD CAPITAL MANAGEMENT LLC
$281.5M604,420 sh
ACADIAN ASSET MANAGEMENT LLC
$211.0M453,238 sh
STATE STREET CORP
$207.1M444,716 sh
GEODE CAPITAL MANAGEMENT, LLC
$192.8M413,942 sh
JPMORGAN CHASE & CO
$185.8M403,395 sh
Boston Partners
$130.7M280,684 sh
Epoch Investment Partners, Inc.
$124.5M267,290 sh

Fund	Value	Shares
BlackRock, Inc.	$691.3M	1,484,282
AQR CAPITAL MANAGEMENT LLC	$446.2M	972,474
VANGUARD PORTFOLIO MANAGEMENT LLC	$366.6M	787,068
VANGUARD CAPITAL MANAGEMENT LLC	$281.5M	604,420
ACADIAN ASSET MANAGEMENT LLC	$211.0M	453,238
STATE STREET CORP	$207.1M	444,716
GEODE CAPITAL MANAGEMENT, LLC	$192.8M	413,942
JPMORGAN CHASE & CO	$185.8M	403,395
Boston Partners	$130.7M	280,684
Epoch Investment Partners, Inc.	$124.5M	267,290

Companies Similar to CHE

Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.

PODD

INSULET CORP

AI score

Very similar · 16 shared holders

FRONTIER CAPITAL MANAGEMENT CO LLC VOLORIDGE INVESTMENT MANAGEMENT, LLC CAISSE DE DEPOT ET PLACEMENT DU QUEBEC

MEDP

Medpace Holdings, Inc.

AI score

Similar quality profile · 18 shared holders

Epoch Investment Partners, Inc.FULLER & THALER ASSET MANAGEMENT, INC.Boston Trust Walden Corp

EHC

Encompass Health Corp

AI score

Similar quality profile · 26 shared holders

FULLER & THALER ASSET MANAGEMENT, INC.Copeland Capital Management, LLC Eversept Partners, LP

WST

WEST PHARMACEUTICAL SERVICES INC

AI score

Similar quality profile · 10 shared holders

Epoch Investment Partners, Inc.Boston Trust Walden Corp Candriam S.C.A.

Edwards Lifesciences Corp

AI score

Similar quality profile · 13 shared holders

CAISSE DE DEPOT ET PLACEMENT DU QUEBEC Boston Trust Walden Corp Candriam S.C.A.

IQV

IQVIA HOLDINGS INC.

AI score

Similar quality profile · 9 shared holders

Boston Partners JUPITER ASSET MANAGEMENT LTD Candriam S.C.A.

SYK

STRYKER CORP

AI score

Similar quality profile · 13 shared holders

Boston Partners Boston Trust Walden Corp FORT WASHINGTON INVESTMENT ADVISORS INC /OH/

GRDN

Guardian Pharmacy Services, Inc.

AI score

Similar quality profile · 7 shared holders

Boston Partners Aristotle Capital Boston, LLC LOOMIS SAYLES & CO L P

Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put CHE on your watchlist

Track score changes the day CHEMED CORP files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is CHE a good stock to buy?

13F Pro's AI-powered analysis of CHEMED CORP (CHE) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on NYSE). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for CHE are available on the CHE stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. CHE is classified as a mid company.

Which hedge funds own CHE?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling CHE. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of CHEMED CORP's investment landscape.